Sanofi GMP Problems Require Top-level Sit-down With FDA, But Product Impact Limited So Far
Executive Summary
Agency’s warning letter also includes an uncommon request for a “global assessment” of operations. FDA says sterility of TheraCys lots manufactured since 2000 cannot be assured; company has halted manufacture of the bladder cancer drug and set limits on orders of its Pentacel vaccine.
You may also be interested in...
A Closer Look: Is Double-Digit Growth Sustainable In Emerging Markets? (Part 1 of 2)
A new debate among investors concerns whether double-digit growth is possible across emerging markets or only in China. PharmAsia News takes a closer look.
Sandoz GMP Warning Letter: Is The Problem Documentation, Or Leadership?
Upper management at Novartis and Sandoz are responsible for repeated cGMP violations at three Sandoz plants, FDA suggests. The agency’s warning letter, aimed at three sites in North Amercia, includes what may become new biolerplate instructions on drug shortages.
Sanofi Lacks System To Prevent Microbial Contamination At Its German Plant, FDA Says
Sanofi-Aventis has not established or followed appropriate written procedures to prevent microbiological contamination of drug products at its manufacturing facility in Frankfurt, FDA told the company.